References
1
Beuers
U, Gershwin ME, Gish RG, et al. . Changing nomenclature for PBC:
From ’cirrhosis’ to ’cholangitis’. J Hepatol 2015;63: 1285-7.
2
Selmi
C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet
2011;377: 1600-9.
3
Lindor
KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis:
2018 Practice Guidance from the American Association for the Study of
Liver Diseases. Hepatology 2019;69: 394-419.
4
Bianchi
I, Lleo A, Gershwin ME, Invernizzi P. The X chromosome and immune
associated genes. J Autoimmun 2012;38: J187-92.
5
Kaplan
MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med
2005;353: 1261-73.
6
Shimoda
S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4
0101-restricted immunodominant T cell autoepitope of pyruvate
dehydrogenase complex in primary biliary cirrhosis: Evidence of
molecular mimicry in human autoimmune diseases. J Exp Med
1995;181: 1835-45.
7 Kita
H, Lian ZX, Van de Water J, et al. . Identification of
HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary
cirrhosis: T cell activation is augmented by immune complexes
cross-presented by dendritic cells. J Exp Med 2002;195: 113-23.
8
Konecki
DS, Foetisch K, Zimmer KP, Schlotter M, Lichter-Konecki U. An
alternatively spliced form of the human lysosome-associated membrane
protein-2 gene is expressed in a tissue-specific manner. Biochem Biophys
Res Commun 1995;215: 757-67.
9
Cuervo
AM, Dice JF. Unique properties of lamp2a compared to other lamp2
isoforms. J Cell Sci 2000;113 Pt 24: 4441-50.
10
Bandyopadhyay
U, Cuervo AM. Entering the lysosome through a transient gate by
chaperone-mediated autophagy. Autophagy 2008;4: 1101-3.
11
Valdor
R, Mocholi E, Botbol Y, et al. . Chaperone-mediated autophagy
regulates T cell responses through targeted degradation of negative
regulators of T cell activation. Nat Immunol 2014;15: 1046-54.
12
Nakagawa
R, Muroyama R, Saeki C, et al. . CD4(+) T cells from patients with
primary biliary cholangitis show T cell activation and differentially
expressed T-cell receptor repertoires. Hepatol Res
2019;49: 653-62.
13 Jin
Q, Moritoki Y, Lleo A, et al. . Comparative analysis of portal
cell infiltrates in antimitochondrial autoantibody-positive versus
antimitochondrial autoantibody-negative primary biliary cirrhosis.
Hepatology 2012;55: 1495-506.
14
Yang
CY, Ma X, Tsuneyama K, et al. . IL-12/Th1 and IL-23/Th17 biliary
microenvironment in primary biliary cirrhosis: Implications for therapy.
Hepatology 2014;59: 1944-53.
15
EASL
Clinical Practice Guidelines: The diagnosis and management of patients
with primary biliary cholangitis. J Hepatol 2017;67: 145-72.
16
Manns
MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D,
Vierling JM. Diagnosis and management of autoimmune hepatitis.
Hepatology 2010;51: 2193-213.
17 Ho
PW, Leung CT, Liu H, et al. . Age-dependent accumulation of
oligomeric SNCA/alpha-synuclein from impaired degradation in mutant
LRRK2 knockin mouse model of Parkinson disease: Role for therapeutic
activation of chaperone-mediated autophagy (CMA). Autophagy
2019: 1-24.
18
Ludwig
J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative
destructive cholangitis (syndrome of primary biliary cirrhosis).
Virchows Arch A Pathol Anat Histol 1978;379: 103-12.
19
Jansen
PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J, Hengstler JG. The
ascending pathophysiology of cholestatic liver disease. Hepatology
2017;65: 722-38.
20
Gershwin
ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and
inconvenient truths. Hepatology 2008;47: 737-45.
21
Rong
G, Zhong R, Lleo A, et al. . Epithelial cell specificity and
apotope recognition by serum autoantibodies in primary biliary
cirrhosis. Hepatology 2011;54: 196-203.
22
Kita
H, Matsumura S, He XS, et al. . Quantitative and functional
analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in
primary biliary cirrhosis. J Clin Invest 2002;109: 1231-40.
23
Nakamura
M, Ishibashi H, Matsui M, Shimoda S, Hayashida K, Koike K, Niho Y.
Peripheral B lymphocyte repertoire to mitochondrial antigen in primary
biliary cirrhosis–positive correlation between the disease activity
and the frequency of circulating B lymphocytes specific for pyruvate
dehydrogenase complex. Autoimmunity 1995;21: 253-62.
24
Gershwin
ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of
a cDNA encoding the 70 kd mitochondrial antigen recognized in primary
biliary cirrhosis. J Immunol 1987;138: 3525-31.
25
Hirschfield
GM, Gershwin ME. The immunobiology and pathophysiology of primary
biliary cirrhosis. Annu Rev Pathol 2013;8: 303-30.
26
Hashimoto
E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, Ludwig J.
Immunohistochemical characterization of hepatic lymphocytes in primary
biliary cirrhosis in comparison with primary sclerosing cholangitis and
autoimmune chronic active hepatitis. Mayo Clin Proc
1993;68: 1049-55.
27
Hirschfield
GM, Liu X, Xu C, et al. . Primary biliary cirrhosis associated
with HLA, IL12A, and IL12RB2 variants. N Engl J Med
2009;360: 2544-55.
28 Liu
X, Invernizzi P, Lu Y, et al. . Genome-wide meta-analyses identify
three loci associated with primary biliary cirrhosis. Nat Genet
2010;42: 658-60.
29 Qiu
F, Tang R, Zuo X, et al. . A genome-wide association study
identifies six novel risk loci for primary biliary cholangitis. Nat
Commun 2017;8: 14828.
30
Yoshida
K, Yang GX, Zhang W, et al. . Deletion of interleukin-12p40
suppresses autoimmune cholangitis in dominant negative transforming
growth factor beta receptor type II mice. Hepatology
2009;50: 1494-500.
31
Ferenczi
K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R
identify persistently activated T cells in psoriasis vulgaris lesional
skin: Blood and skin comparisons by flow cytometry. J Autoimmun
2000;14: 63-78.
32
Tafuri
A, Shahinian A, Bladt F, et al. . ICOS is essential for effective
T-helper-cell responses. Nature 2001;409: 105-9.
33
Tesciuba
AG, Shilling RA, Agarwal MD, et al. . ICOS costimulation expands
Th2 immunity by augmenting migration of lymphocytes to draining lymph
nodes. J Immunol 2008;181: 1019-24.
34
Paulos
CM, Carpenito C, Plesa G, et al. . The inducible costimulator
(ICOS) is critical for the development of human T(H)17 cells. Sci Transl
Med 2010;2: 55r-78r.
35
Nagano
T, Yamamoto K, Matsumoto S, et al. . Cytokine profile in the liver
of primary biliary cirrhosis. J Clin Immunol 1999;19: 422-7.
36
Nagano
T, Yamamoto K, Matsumoto S, et al. . Cytokine profile in the liver
of primary biliary cirrhosis. J Clin Immunol 1999;19: 422-7.
37
Crotzer
VL, Glosson N, Zhou D, Nishino I, Blum JS. LAMP-2-deficient human B
cells exhibit altered MHC class II presentation of exogenous antigens.
Immunology 2010;131: 318-30.
38
Zhou
D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS.
Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens.
Immunity 2005;22: 571-81.
39
Perez
L, McLetchie S, Gardiner GJ, Deffit SN, Zhou D, Blum JS. LAMP-2C
inhibits MHC class II presentation of cytoplasmic antigens by disrupting
Chaperone-Mediated autophagy. J Immunol 2016;196: 2457-65.
40
Wang
L, Guo G, Wang J, et al. . A decline of LAMP- 2 predicts
ursodeoxycholic acid response in primary biliary cirrhosis. Sci Rep-Uk
2015;5 .